BRISTOL-MYERS SQUIBB CO
BMYNYSETrading Snapshot
- Day Range
- $62.43 β $63.62
- 52-Week Range
- $42.52 β $68.64
- Volume
- $6.25B
- Avg Volume
- $5.17B
- Shares Outstanding
- 2.04B
- Next Earnings
- Nov 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $48.20B
- Last Q Revenue
- $12.97B
- P/E Ratio
- 14.1
- P/S Ratio
- 2.7x
- EPS (TTM)
- $4.55
- Dividend Yield
- 3.93%
- Dilution (1yr)
- +0.2%
Why Investors Own BMY
- βHigh-growth profile β revenue up +2.6% YoY with expanding Biotech exposure.
- βHealthy economics β 37% gross margin and 17% free-cash-flow margin.
- βDeep pipeline with potential catalysts and durable IP.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BRISTOL-MYERS SQUIBB CO
BMYAbout BRISTOL-MYERS SQUIBB CO
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
BRISTOL-MYERS SQUIBB CO tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift BMY price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
BRISTOL-MYERS SQUIBB CO announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.